Description:

S0502 Cycle-Specific Treatment Form S0502 Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBF7C37-6B6E-72A0-E034-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FCBF7C37-6B6E-72A0-E034-0003BA3F9857

Keywords:
Versions (2) ▾
  1. 9/19/12
  2. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Gastrointestinal Stromal Tumor NCT00324987 Treatment - S0502 Cycle-Specific Treatment Form - 2320335v1.0

Intergroup Coalition Against Sarcomas (ICAS)

  1. StudyEvent: S0502 Cycle-Specific Treatment Form
    1. Intergroup Coalition Against Sarcomas (ICAS)
Header
Status
Vital Status
Has the patient progressed per the definition of Section 10.0 of the protocol?
Treatment For This Cycle
Kg
Were there any dose modifications or additions/omissions to protocol treatment?
Units
Dose modification
Dose Modification Reason
Modification due to Adverse Event
Comments

Similar models